ISB News

Participatory Medicine Q&A with Lee Hood

Genome Medicine featured ISB's Dr. Lee Hood in a series about participatory medicine.

Genome Medicine created a participatory medicine series, which was guest edited by Dr. Lee Hood, president of Institute for Systems Biology, and Dr. Charles Auffray, Founding Director of the European Institute for Systems Biology and Medicine. You can read the collection of articles on participatory medicine here. It includes an editorial "Participatory medicine: a driving force for revolutionizing healthcare" co-authored by Hood and Auffray that was published in December 2013.

Genome Medicine senior assistant editor, Andreia Cunha, also produced an accompanying podcast that features in interview with Hood. Listen to the podcast.

Read the Q&A with Lee Hood about participatory medicine that was featured in BioMed Central's Biome Magazine.

Excerpt:

How would you define participatory medicine?

Participatory medicine actually has many different components. I’d say, first of all, there is a big revolution coming in healthcare. That revolution is reflected in several different names: systems medicine, P4 medicine (predictive, preventive, personalized and participatory), or personalized medicine. In a sense, each of these names reflects variations on the theme of data-driven personalized medicine. This concept encompasses the idea that soon each patient will be surrounded by a virtual cloud of billions of data points and that we will have the computational analytics to integrate these data and reduce their enormous dimensionality to simple hypotheses about how to optimize wellness and minimize disease for each individual. — Dr. Lee Hood from a Genome Medicine Q&A

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.